Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Optimizing the management of her2-positive early breast cancer: The clinical reality

Publication ,  Journal Article
Verma, S; Lavasani, S; Mackey, J; Pritchard, K; Clemons, M; Dent, S; Latreille, J; Lemieux, J; Provencher, L; Chia, S; Wang, B; Rayson, D
Published in: Current Oncology
January 1, 2010

Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with her2-positive breast cancer. In that population, trastuzumab has been studied in six randomized clinical trials. Overall, use of this agent leads to a significant reduction in risk of disease recurrence and improvement in overall survival. Despite the strong evidence for the use of trastuzumab in managing her2-positive early breast cancer (ebc), a number of clinical controversies remain. The authors of this paper undertook a review of the available scientific literature on adjuvant trastuzumab to produce practical considerations from Canadian oncologists. The panel focused their discussion on five key areas: {filled circle} Management of node-negative disease with tumours 1 cm or smaller in size {filled circle} Management of her2-positive ebc across the spectrum of the disease (that is, nodal and steroid hormone receptor status, tumour size) {filled circle} Timing of trastuzumab therapy with chemotherapy for early-stage disease: concurrent or sequential {filled circle} Treatment duration of trastuzumab for ebc {filled circle} The role of non-anthracycline trastuzumab-based regimens.©2010 Multimed Inc.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Current Oncology

DOI

EISSN

1718-7729

Publication Date

January 1, 2010

Volume

17

Issue

4

Start / End Page

20 / 33

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Verma, S., Lavasani, S., Mackey, J., Pritchard, K., Clemons, M., Dent, S., … Rayson, D. (2010). Optimizing the management of her2-positive early breast cancer: The clinical reality. Current Oncology, 17(4), 20–33. https://doi.org/10.3747/co.v17i4.700
Verma, S., S. Lavasani, J. Mackey, K. Pritchard, M. Clemons, S. Dent, J. Latreille, et al. “Optimizing the management of her2-positive early breast cancer: The clinical reality.” Current Oncology 17, no. 4 (January 1, 2010): 20–33. https://doi.org/10.3747/co.v17i4.700.
Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, et al. Optimizing the management of her2-positive early breast cancer: The clinical reality. Current Oncology. 2010 Jan 1;17(4):20–33.
Verma, S., et al. “Optimizing the management of her2-positive early breast cancer: The clinical reality.” Current Oncology, vol. 17, no. 4, Jan. 2010, pp. 20–33. Scopus, doi:10.3747/co.v17i4.700.
Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Chia S, Wang B, Rayson D. Optimizing the management of her2-positive early breast cancer: The clinical reality. Current Oncology. 2010 Jan 1;17(4):20–33.

Published In

Current Oncology

DOI

EISSN

1718-7729

Publication Date

January 1, 2010

Volume

17

Issue

4

Start / End Page

20 / 33

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis